Animal healthcare company, Hester Biosciences has recently reported a strong growth in Q2 and H1 FY 2014-15 results. Hester has reported a net profit for Q2 at Rs 2.74 crores as against Rs 1.65 crores for the previous corresponding period, thereby registering a growth of 66.65 per cent. It posted net sales of Rs 21.49 crores in Q2 ended September 30, 2014 as compared to Rs 15.29 crores for the previous corresponding period, thereby registering a growth of 40.51 per cent. Earnings per share for the quarter ended on September 30, 2014 is at Rs 3.22 as against Rs 1.94 for the quarter ended on September 30, 2013.
Hester has reported a net profit for H1 at Rs 7.08 crores as against Rs 3.63 crores for the previous corresponding period, thereby registering a growth of 95.23 per cent. Net sales of Rs 44.79 crore in H1 ended 30 September 2014 as compared to Rs 31.34 crore for the previous corresponding period, thereby registering a growth of 42.94 per cent. Earnings per share for H1 ended on September 30, 2014 is at Rs 8.33 as against Rs 4.27 for the H1 ended on 30 September 2013.
Rajiv Gandhi, Chief Executive Officer and Managing Director, Hester Biosciences mentioned that all financial targets of H1 have been met. Three verticals (poultry vaccines, poultry health products and large animal health products) have shown a sizable improvement in top line and in bottom line. Business in the fourth vertical, large animal vaccines, will commence in the last quarter of this financial year.
EP News Bureau– Mumbai
